REPUBLIC HC (Republic Healthcare Limited) reported interim results for the six months ended 30 June 2026.
Revenue and Profitability – Revenue reached S$4.15 million, up 11.2% from S$3.73 million a year earlier, driven by a 10.4% uptick in medical-segment sales. – Gross profit increased 12.4% to S$2.90 million; gross margin was broadly stable. – Net loss attributable to shareholders expanded to S$1.58 million from S$1.24 million, mainly reflecting a S$0.61 million rise in employee benefits linked to expanded PRC operations and higher depreciation and lease-related finance costs. – Other operating expenses fell S$0.34 million due to reduced foreign-exchange losses.
Segment Breakdown – Treatment services generated S$2.52 million, accounting for 60.7% of total revenue. – Medical investigation services contributed S$1.07 million (25.7%). – Consultation services delivered S$0.54 million (12.9%). – A new healthcare-education unit added S$0.03 million.
Cash Flow and Balance Sheet – Net cash used in operations was S$0.61 million; total cash and equivalents declined to S$4.98 million from S$6.41 million at end-2025. – Total assets stood at S$12.88 million (31 Dec 2025: S$16.14 million). – Net assets decreased to S$7.97 million (31 Dec 2025: S$9.55 million). – The group remained debt-free; lease liabilities were S$3.42 million, giving a gearing ratio of 43% (31 Dec 2025: 53%).
Capital Moves and Post-period Events – In April 2026, a subsidiary agreed to buy a Singapore property for S$1.03 million. – In May 2026, a Shenzhen office lease signed in 2025 was terminated. – On 31 July 2026, the group agreed to sell its entire interest in Life Ark (Shenzhen) Technology for RMB13.70 million (about HK$15.76 million); completion will remove the unit from consolidation.
Funding and Dividends – IPO and September 2021 placing proceeds totaling S$12.70 million have been fully deployed, mainly for clinic expansion, staffing and IT upgrades. – The board declared no interim dividend.
Outlook Management will prioritise improving operational efficiency across its five Singapore DTAP clinics, pursue disciplined cost control and evaluate strategic collaborations, including the previously announced potential investment in Langgu Bio, subject to due diligence and approvals.